A new 1,2,3-triazole-indirubin hybrid suppresses tumor growth and pulmonary metastasis by mitigating the HGF/c-MET axis in hepatocellular carcinoma

Key Points

• Tumor growth suppression is observed, indicating effectiveness in treatment.
• The hybrid compound targets the HGF/c-MET signaling pathway, reducing metastasis rates.
• Assessment using the hybrid compound demonstrates promise in preventing aggressive cancer spread.
• This highlights the potential of new therapeutic strategies in managing hepatocellular carcinoma.